CMR Surgical has completed a financing round of more than $200m, combining equity and debt capital to expedite the commercialisation of its Versius Surgical Robotic System, particularly focusing on the US market. Through these funds, the company also aims to bolster its growth strategy. The financing round is supported by all current investors and includes a debt investment from alternative asset manager Trinity Capital, which has pledged up to $68.75m in growth capital to the company as part of this current financing initiative. The funds will also support ongoing innovation and product development, including the introduction of the enhanced Versius Plus. Armentum Partners served as the company’s financial adviser for the debt financing of the funding round. Deployed in more than 30,000 surgeries across over 30 nations so far, the Versius system aims to enhance surgical procedures. It received de novo marketing clearance from the US Food and Drug Administration (FDA) last year for cholecystectomy procedures in adults aged over 22.

Full report : Heath care startup CMR Surgical secures over $200 million US robotic surgery rollout.